Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
Breaking Biotech - 028 - ASH 2018 Updates!

028 - ASH 2018 Updates!

12/12/18 • 24 min

Breaking Biotech

Lots has happened since my last video! Today I talk about the updates from ASH 2018, with a focus on $BLUE and $GBT. I also talk about FATE, $MRNA, and the companies making bispecifics.

This is not investment advice, but for information only.

www.breakingbiotech.com

plus icon
bookmark

Lots has happened since my last video! Today I talk about the updates from ASH 2018, with a focus on $BLUE and $GBT. I also talk about FATE, $MRNA, and the companies making bispecifics.

This is not investment advice, but for information only.

www.breakingbiotech.com

Previous Episode

undefined - 027 - Amarin Sells Off Amid Positive Vascepa Data

027 - Amarin Sells Off Amid Positive Vascepa Data

Amarin recently published data from their REDUCE-IT cardiovascular outcomes trial. Their EPA medicine, Vascepa, showed a 25% relative risk reduction compared to placebo. EPA is an omega-3 fatty acid that previously showed a 19% relative risk reduction in cardiovascular outcomes in a Japanese study (JELIS, 2007). Amarin saw a hazard ratio of 0.75 in their primary endpoint, which evaluated cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and unstable angina. In this video, I go through two critiques of the study: 1) Lack of mechanistic insight 2) Mineral oil use in the placebo group I believe Vascepa is likely to get FDA approval for the indication of reducing cardiovascular disease in patients with over 150mg/dl Triglycerides on statin therapy.

This is not investment advice, do your own due diligence.

Relevant links: https://investor.amarincorp.com/ https://www.nejm.org/doi/full/10.1056/NEJMoa1812792 https://www.nejm.org/doi/full/10.1056/NEJMe1814004

Next Episode

undefined - 029 - Powell ruins the market. DBVT pulls BLA!

029 - Powell ruins the market. DBVT pulls BLA!

Hey everybody, I hope you've all been enjoying the holidays. I talk about 3 things in this video:

  1. The federal reserve and chairman Powell's comments on their guidance and the economy.
  2. DBVT pulling their BLA and my opinion on both them and AIMT.
  3. CRISPR/Cas9 and the companies commercializing the tech.

This is only my opinion and should not be considered financial advice

www.breakingbiotech.com https://youtu.be/Bi-LFgexGSc

Episode Comments

Generate a badge

Get a badge for your website that links back to this episode

Select type & size
Open dropdown icon
share badge image

<a href="https://goodpods.com/podcasts/breaking-biotech-130757/028-ash-2018-updates-6467921"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to 028 - ash 2018 updates! on goodpods" style="width: 225px" /> </a>

Copy